Welcome to our dedicated page for Sana Biotechnology SEC filings (Ticker: SANA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sana Biotechnology鈥檚 engineered-cell breakthroughs are exciting鈥攜et their regulatory filings can feel like advanced immunology textbooks. Clinical trial updates, gene-editing methods and cash-runway calculations are scattered across hundreds of pages, leaving analysts asking how to extract the essentials before the market moves.
Stock Titan solves that problem. Our AI reads every Sana Biotechnology quarterly earnings report 10-Q filing and annual report 10-K simplified, then delivers plain-English takeaways on pipeline progress and balance-sheet strength. Need real-time alerts? We push Sana Biotechnology Form 4 insider transactions real-time so you can track executive stock transactions Form 4 the moment they post. From a sudden 8-K material events explained to a detailed proxy statement executive compensation table, we keep the entire library鈥�10-K, 10-Q, 8-K, S-1, DEF 14A鈥攗pdated within minutes of hitting EDGAR.
Whether you鈥檙e monitoring Sana Biotechnology insider trading Form 4 transactions for confidence signals, comparing R&D spend through Sana Biotechnology earnings report filing analysis, or simply understanding Sana Biotechnology SEC documents with AI, our platform turns technical language into actionable context. Find every HIP platform disclosure, follow funding milestones, and answer natural questions like 鈥淪ana Biotechnology SEC filings explained simply鈥� without wading through PDFs. Critical biotech data, delivered clearly鈥攕o you can focus on decisions, not document hunts.
Sana Biotechnology reported continued development-stage losses and significant balance sheet changes through June 30, 2025. The company recorded a six-month net loss of $143.2 million and a three-month loss of $93.8 million, driven in part by a $44.6 million non-cash impairment of long-lived assets related to its Bothell and Seattle facilities. Total assets fell to $361.6 million from $501.0 million at year-end, and cash and cash equivalents declined to $71.3 million on the balance sheet. Long-term liabilities include $117.1 million of contingent consideration and $8.6 million of success payment liabilities tied to prior acquisitions and license agreements. Management completed an ATM facility and, subsequently, an underwritten offering that together provided additional net proceeds (including $70.0 million from the August offering and $28.6 million raised under the ATM after June 30), and believes available liquidity plus those proceeds will fund planned operations for at least one year. The company reported positive clinical signals for an investigator-sponsored islet transplant (UP421), including C-peptide production and PET-MRI evidence of engraftment, and announced portfolio prioritization toward T1D, B-cell autoimmune diseases, refractory B-cell malignancies, and the fusogen platform.
Sana Biotechnology announced it has issued a press release reporting its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Form 8-K. The company states the press release is being furnished and not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless explicitly stated. The 8-K lists Exhibit 99.1 and an Inline XBRL cover page, identifies the registrant as an emerging growth company, and is signed by Acting Chief Financial Officer Susan Wyrick. The company trades on Nasdaq under the ticker SANA.
On 6-Aug-2025 Sana Biotechnology, Inc. (SANA) executed an Underwriting Agreement with Morgan Stanley, Goldman Sachs and BofA to raise capital through a public offering.
- Securities: 20,895,522 common shares at $3.35 and 1,492,537 pre-funded warrants at $3.3499 per underlying share.
- Underwriter purchase price: $3.149 per share and $3.1489 per warrant.
- Greenshoe: 30-day option for up to 3,358,208 additional shares.
- Net proceeds: 鈮�$70 million to SANA, assuming no option exercise and after fees.
- Closing: expected 8-Aug-2025, subject to customary conditions.
- Warrant terms: $0.0001 exercise price, no expiration, 4.99 % ownership cap (adjustable to 鈮�19.99 %), cash or cashless exercise, standard anti-dilution and Fundamental Transaction protections.
The raise is being made from shelf registration statement No. 333-277584. All securities are issued by the company, providing immediate liquidity while increasing the share count and potential future dilution.
Sana Biotechnology (NASDAQ: SANA) filed an 8-K disclosing key Q2-Q3 developments. The company estimates it held $90.1 million in cash, cash equivalents and marketable securities on 31 Jul 2025. Between 1 Apr and 6 Aug 2025 it raised $29.1 million of net proceeds through the sale of 7,441,376 common shares under its at-the-market program.
Sana will record a $40-45 million non-cash impairment in May 2025 linked to suspended build-out and planned subleases of its Bothell and Seattle facilities. Operationally, June 2025 six-month data from the investigator-sponsored UP421 trial met all primary and secondary endpoints, demonstrating insulin-producing 尾-cell function without immunosuppression; results were later published in NEJM. Pre-clinical candidate SC451 advanced following a favorable FDA INTERACT meeting. Conversely, Senior VP & Head of the Hypoimmune Platform Dr. Sonja Schrepfer resigned. All financial figures are unaudited and subject to change.
Sana Biotechnology, Inc. (NASDAQ: SANA) filed a Form 8-K to disclose a material scientific milestone. On June 23 2025, the company announced positive six-month results from an investigator-sponsored, first-in-human study evaluating UP421鈥攁n allogeneic primary islet cell therapy engineered with Sana鈥檚 proprietary hypoimmune technology鈥攊n a patient with type 1 diabetes. Notably, the transplant was performed without any immunosuppression, underscoring a key differentiator of the platform. The announcement was furnished as Exhibit 99.1 to the report and no other financial metrics, earnings data or transactions were included.
The filing is limited to Item 8.01 (Other Events) and Item 9.01 (Exhibits). It confirms that the press release dated June 23 2025 is now part of the public record. No changes to guidance, capitalization or management were reported. The disclosure highlights continued progress of Sana鈥檚 cell-engineering pipeline and potentially de-risks the hypoimmune approach, but investors must await fuller clinical datasets before drawing definitive efficacy or commercial conclusions.
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
What is the market cap of Sana Biotechnology (SANA)?
